Effect of specialized pro-resolving lipid mediators in the regulation of vascular tone and inflammation in human saphenous vein

被引:2
作者
Celik, Zeynep [1 ,2 ]
Ozen, Gulsev [1 ]
Sunar, Seynur [1 ,2 ]
Turkyilmaz, Saygin [3 ]
Turkyilmaz, Gulsum [3 ]
Kavala, Ali Aycan [3 ]
Teskin, Onder [4 ]
Dogan, B. Sonmez Uydes [1 ]
Topal, Gokce [1 ]
机构
[1] Istanbul Univ, Fac Pharm, Dept Pharmacol, TR-34116 Istanbul, Turkiye
[2] Istanbul Univ, Inst Grad Studies Hlth Sci, Dept Pharmacol, Istanbul, Turkiye
[3] Bakirkoy Dr Sadi Konuk Educ & Res Hosp Bakirkoy, Dept Cardiovasc Surg, Istanbul, Turkiye
[4] Biruni Univ, Dept Cardiovasc Surg, Istanbul, Turkiye
关键词
Specialized pro-resolving lipid mediators; Omega polyunsaturated fatty acids; Human saphenous vein; Vascular tone; Vascular inflammation; FATTY-ACIDS; IN-VITRO; RESOLUTION; D1; SUPPLEMENTATION; CELLS; D2;
D O I
10.1016/j.prostaglandins.2023.106786
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Specialized pro-resolving lipid mediators (SPMs), derived from polyunsaturated fatty acids are important mediators in the resolution of inflammation. Recent studies have focused on the effects of SPMs in cardiovascular health and diseases. However, little is known about the effect SPMs on human vascular tone. Therefore, in this study it is aimed to investigate the effect of various SPMs including resolvin D- and E-series, maresin-1 (MaR1) and lipoxin-A4 (LxA4) on the vascular tone of human isolated saphenous vein (SV) preparations under inflammatory conditions. In addition, we aimed to evaluate the effects of SPMs on the release of pro-inflammatory mediators, monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF- alpha) from human SV. Pretreatment of isolated of human SV with resolvin E1 (RvE1), resolvin D1 (RvD1) and MaR1 (100 nM, 18 h) significantly reduced the contractile responses to thromboxane A2 mimetic, U46619 whereas pretreatment with LxA4 and RvD2 (100 nM, 18 h) had no significant effect on the vascular tone of SV. Moreover, RvE1, RvD1 and MaR1 but not LxA4 and RvD2 (100 nM, 18 h) pretreatment diminished the release of MCP-1 and TNF-alpha from SV. In conclusion, our findings suggest that pre-treatment with RvE1, RvD1, and MaR1 could have potential benefits in decreasing graft vasospasm and vascular inflammation in SV.
引用
收藏
页数:9
相关论文
共 43 条
[31]   Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension [J].
Ozen, Gulsev ;
Benyahia, Chabha ;
Mani, Salma ;
Boukais, Kamel ;
Silverstein, Adam M. ;
Bayles, Richard ;
Nelsen, Andrew C. ;
Castier, Yves ;
Danel, Claire ;
Mal, Herve ;
Clapp, Lucie H. ;
Longrois, Dan ;
Norel, Xavier .
BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (01) :161-174
[32]   Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI2: a safer alternative to COX-2 inhibition [J].
Ozen, Gulsev ;
Gomez, Ingrid ;
Daci, Armond ;
Deschildre, Catherine ;
Boubaya, Lilia ;
Teskin, Onder ;
Uydes-Dogan, B. Sonmez ;
Jakobsson, Per-Johan ;
Longrois, Dan ;
Topal, Gokce ;
Norel, Xavier .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (22) :4087-4098
[33]   Control of human vascular tone by prostanoids derived from perivascular adipose tissue [J].
Ozen, Gulsev ;
Topal, Gokce ;
Gomez, Ingrid ;
Ghorreshi, Arezou ;
Boukais, Kamel ;
Benyahia, Chabha ;
Kanyinda, Larry ;
Longrois, Dan ;
Teskin, Onder ;
Uydes-Dogan, B. Sonmez ;
Norel, Xavier .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2013, 107 :13-17
[34]   Proresolution Lipid Mediators in Multiple Sclerosis - Differential, Disease Severity-Dependent Synthesis - A Clinical Pilot Trial [J].
Pruess, Harald ;
Rosche, Berit ;
Sullivan, Aaron B. ;
Brommer, Benedikt ;
Wengert, Oliver ;
Gronert, Karsten ;
Schwab, Jan M. .
PLOS ONE, 2013, 8 (02)
[35]   Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo [J].
Schepers, A. ;
Eefting, D. ;
Bonta, P. I. ;
Grimbergen, J. M. ;
de Vries, M. R. ;
van Weel, V. ;
de Vries, C. J. ;
Egashira, K. ;
van Bockel, J. H. ;
Quax, P. H. A. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (09) :2063-2069
[36]   Pro-resolving lipid mediators are leads for resolution physiology [J].
Serhan, Charles N. .
NATURE, 2014, 510 (7503) :92-101
[37]  
Spite M., 2017, Cell. Mech. Clin., P1447, DOI [10.1002/9783527692156.ch57, DOI 10.1002/9783527692156.CH57]
[38]   Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice [J].
Viola, Joana R. ;
Lemnitzer, Patricia ;
Jansen, Yvonne ;
Csaba, Gergely ;
Winter, Carla ;
Neideck, Carlos ;
Silvestre-Roig, Carlos ;
Dittmar, Gunnar ;
Doering, Yvonne ;
Drechsler, Maik ;
Weber, Christian ;
Zimmer, Ralf ;
Cenac, Nicolas ;
Soehnlein, Oliver .
CIRCULATION RESEARCH, 2016, 119 (09) :1030-1038
[39]   Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study [J].
Wang, Xiuzhe ;
Hjorth, Erik ;
Vedin, Inger ;
Eriksdotter, Maria ;
Freund-Levi, Yvonne ;
Wahlund, Lars-Olof ;
Cederholm, Tommy ;
Palmblad, Jan ;
Schultzberg, Marianne .
JOURNAL OF LIPID RESEARCH, 2015, 56 (03) :674-681
[40]   MARESIN 1 INHIBITS EPITHELIAL-TO-MESENCHYMAL TRANSITION IN VITRO AND ATTENUATES BLEOMYCIN INDUCED LUNG FIBROSIS IN VIVO [J].
Wang, Yaxin ;
Li, Ruidong ;
Chen, Lin ;
Tan, Wen ;
Sun, Zhipeng ;
Xia, Haifa ;
Li, Bo ;
Yu, Yuan ;
Gong, Jie ;
Tang, Min ;
Ji, Yudong ;
Yuan, Shiying ;
Yao, Shanglong ;
Shang, You .
SHOCK, 2015, 44 (05) :496-502